On the stock market since 2015, it operates in the world of health and science. It has 24 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 68% a year over the last 4 years. Red columns mark years that ended in a loss.
The two sides balance each other out — the picture is neither a safety net nor an alarm.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 78% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 117% a year on average.
Over the last 12 months, company executives reported 46 buys and 2 sells. Management buying with its own money is usually read as a good sign.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, KMPH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KMPH is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.